T. Rowe Price Investment Management
ATYR

T. Rowe Price Investment Management’s aTyr Pharma ATYR Stock Holding History

T. Rowe Price Investment Management’s Portfolio ATYR Stock Details ATYR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-141
Closed -$1K – 959
2025
Q3 		$1K Buy
+141
New +$639 ﹤0.01% 879

Other funds holding ATYR

RA
Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

T. Rowe Price Investment Management's ATYR Position: Q4 2025 in Review

T. Rowe Price Investment Management sold out of aTyr Pharma (ATYR) in Q4 2025, closing a stake of 141 shares — an estimated $1K sold.

T. Rowe Price Investment Management first reported a position in ATYR in Q3 2025 and held it in 1 quarter. The position peaked at $1K in Q3 2025. 84 funds tracked by Wall St. Rank hold ATYR as of Q4 2025.

  • T. Rowe Price Investment Management reported no remaining aTyr Pharma position as of Q4 2025 after selling out during the quarter.
  • T. Rowe Price Investment Management sold 141 aTyr Pharma shares in Q4 2025, an estimated $1K.
  • T. Rowe Price Investment Management first reported a position in aTyr Pharma in Q3 2025 and held it in 1 quarter.
  • T. Rowe Price Investment Management's aTyr Pharma position peaked at $1K in Q3 2025.
  • 84 funds tracked by Wall St. Rank held aTyr Pharma as of Q4 2025.

Based on T. Rowe Price Investment Management's 13F filing for Q4 2025, filed 17 Feb 2026.